NASDAQ: ASPIAsp Isotopes Inc Stock
$10.13-0.63 (-5.86%)
Updated Oct 31, 2025
ASPI Price
$10.13
Fair Value Price
N/A
Market Cap
$931.08M
52 Week Low
$3.65
52 Week High
$14.49
P/E
-7.24x
P/B
36.9x
P/S
117.29x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.58M
Earnings
-$99.96M
Gross Margin
39.3%
Operating Margin
-2,170.61%
Profit Margin
-2,181.8%
Debt to Equity
4.27
Operating Cash Flow
-$20M
Beta
1.65
Next Earnings
Dec 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ASPI Overview
ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company also Uranium-235, an isotope of uranium for carbon-free energy industry. ASP Isotopes Inc. was incorporated in 2021 and is based in Boca Raton, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASPI's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Chemical
Industry Rating
F
ASPI
Ranked#12 of 14
Ranked#12 of 14
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $18.86 | C | |
| $32.03 | C | |
| $18.59 | C |
Be the first to know about important ASPI news, forecast changes, insider trades & much more!
ASPI News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASPI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASPI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASPI is poor value based on its book value relative to its share price (36.9x), compared to the US Chemicals industry average (0.97x)
P/B vs Industry Valuation
ASPI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ASPI due diligence checks available for Premium users.
Valuation
ASPI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.24x
Industry
-6.61x
Market
41.65x
ASPI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
36.9x
Industry
0.97x
ASPI is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASPI's financial health
Profit margin
Revenue
$1.2M
Net Income
-$75.1M
Profit Margin
-6,263.9%
ASPI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ASPI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$135.9M
Liabilities
$107.6M
Debt to equity
4.27
ASPI's short-term assets ($101.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASPI's short-term assets ($101.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASPI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.9M
Investing
-$31.7M
Financing
$51.0M
ASPI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASPI vs Chemical Stocks
Asp Isotopes Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.